- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT05589753
Søvnforstyrrelse puste med opioidbruk (SDB)
Målretting av kjemoreseptorkontroll av pusten under søvn for å dempe opioidassosiert søvnforstyrrelse
There is an increased risk for sleep disordered breathing (SDB), sleep-related hypoventilation and irregular breathing in individuals on chronic prescription opioid medications. Almost 30% of a veteran sleep clinic population had opioid-associated central sleep apnea (CSA). The proposal aims to identity whether oxygen and acetazolamide can be effective in reducing unstable breathing and eliminating sleep apnea in chronic opioid use via different mechanisms. We will study additional clinical parameters like quality of life, sleep and pain in patients with and without opioid use. This proposal will enhance the investigators' understanding of the pathways that contribute to the development of sleep apnea with opioid use. The investigators expect that the results obtained from this study will positively impact the health of Veterans by identifying new treatment modalities for sleep apnea.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
In a national sample of Veterans, SDB was a significant risk factor for opioid-related toxicity and overdose; and the presence of CSA combined with chronic prescription opioid use compounded the mortality risk. There are only limited and partially effective therapies for this sleep disorder and the exact mechanisms by which opioids produce SDB in adults remain unclear, and varied and conflicting ventilatory control mechanisms have been suggested. This proposal will investigate whether alternative therapies can be developed by modulating specific physiologic mechanisms of ventilatory control. Specifically, the investigators will study effects of chronic oral prescription opioids on chemoresponsiveness and cerebrovascular responsiveness (CVR) (Aim 1); and whether interventions with sustained hyperoxia (Aim 2) and acetazolamide (Aim 3) will reduce the apneic threshold (AT) to alleviate breathing instability and SDB in chronic prescription opioid-associated SDB. The proposed aims will also allow us to delineate key mechanisms of breathing instability with opioid and without opioid use. The information garnered from the proposed experiments will drive development of novel personalized therapies to reduce SDB associated with chronic opioids in Veterans and, ultimately, will positively impact their long-term health and well-being.
Studietype
Registrering (Antatt)
Fase
- Fase 2
- Fase 1
Kontakter og plasseringer
Studiekontakt
- Navn: Ruchi Rastogi, MS
- Telefonnummer: (313) 576-4464
- E-post: ruchi.rastogi@va.gov
Studiesteder
-
-
Michigan
-
Detroit, Michigan, Forente stater, 48201-1916
- Rekruttering
- John D. Dingell VA Medical Center, Detroit, MI
-
Ta kontakt med:
- Ruchi Rastogi, MS
- Telefonnummer: (313) 576-4464
- E-post: ruchi.rastogi@va.gov
-
Hovedetterforsker:
- Susmita Chowdhuri, MD MS
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Veterans, age 18-89 years
- Veterans with prescription opioids
Exclusion Criteria:
- Patients with BMI>40kg/m2 will be excluded to avoid the effects of morbid obesity on pulmonary mechanics and ventilatory control
- Patients with history of unresolved/untreated cardiac disease, including recent myocardial infarction, recent bypass surgery, untreated atrial and ventricular tachy-bradycardias
- Congestive heart failure with Cheyne-Stokes respiration (CSR)
- Current unstable angina
- Recent stroke
- Untreated schizophrenia
- Untreated hypothyroidism
- Unresolved seizure disorder
- Severe respiratory, neurological, liver and renal diseases
- Unstable psychiatric disorders/untreated PTSD
- Traumatic brain injury
- Pregnant women
- Significant sleep disorder such as narcolepsy, parasomnias disorder
- Failure to give informed consent
- Patients on tramadol and suboxone/buprenorphine
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Annen
- Tildeling: Randomisert
- Intervensjonsmodell: Crossover-oppdrag
- Masking: Enkelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Hyperoxia
Determine the effect of sustained hyperoxia overnight vs room air overnight on ventilatory control during sleep, including the apneic threshold, carbon-dioxide reserve and chemosensitivity measured via pressure support ventilation (PSV) during non-rapid eye movement sleep (NREM) sleep. |
The ventilatory effects of brief hyperoxia will be assessed by analyzing control breaths on room air immediately preceding the hyperoxic exposure, and comparing with the primary end-point, nadir minute ventilation breath, immediately following the brief hyperoxic exposure.
Andre navn:
|
|
Eksperimentell: Acetazolamide (ACZ)
Determine the effect of acetazolamide on cerebrovascular responsiveness to CO2 during wake and sleep. Participants will receive oral ACZ therapy for 6 days, While on the medication following studies will be performed - experimental night study, experimental day study, polysomnography night study (PSG). |
Participants with sleep apnea will ingest capsules containing either placebo or acetazolamide 500 mg twice a day for 6 days. On the final 4 consecutive nights while still on ACZ, the investigators will perform i) physiology tests and ii) in-lab follow-up PSG.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Apneic threshold - a measure of breathing instability
Tidsramme: 2 days to 30 days
|
Measures of breathing instability including: Apneic threshold: this is the end-tidal Co2 at which a central apnea closes to a hypopnea is produced. |
2 days to 30 days
|
|
Cerebrovascular responsiveness to carbon-dioxide
Tidsramme: 7 days
|
Cerebrovascular response to different levels of CO2: this is a measure of the response of the cerebral blood flow to changes in carbon dioxide levels and is used as a measure of ventilatory control of breathing |
7 days
|
|
Ventilatory responsiveness
Tidsramme: 2 days to 30 days
|
Hypocapnic ventilatory response; this is calculated as the change in minute ventilation for corresponding changes in PETCO2. |
2 days to 30 days
|
|
Carbon-dioxide reserve
Tidsramme: 2 days to 30 days
|
This is a derived measure. This is calculated as the difference between the apneic threshold PETCO2 (given above) and the control PETCO2. |
2 days to 30 days
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Apnea hypopnea index
Tidsramme: 2 days to 30 days
|
Apnea hypopnea index- is a measure of severity of sleep apnea - this is calculated as the total number of apneas and hypopneas recorded during a sleep study divided by the total sleep time during the sleep study. |
2 days to 30 days
|
Samarbeidspartnere og etterforskere
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Susmita Chowdhuri, MD MS, John D. Dingell VA Medical Center, Detroit, MI
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Sykdommer i nervesystemet
- Sykdommer i luftveiene
- Respirasjonsforstyrrelser
- Søvnvåkenforstyrrelser
- Apné
- Søvnforstyrrelser, iboende
- Dyssomnier
- Søvnapné syndromer
- Svovelforbindelser
- Organiske kjemikalier
- Heterocykliske forbindelser, 1-ring
- Heterocykliske forbindelser
- Thiazoles
- Azoler
- Uorganiske kjemikalier
- Elementer
- Kalkogener
- Thiadiazoles
- Gasser
- Acetazolamid
- Oksygen
Andre studie-ID-numre
- PULM-003-18F
- 1904002203 (Annet stipend/finansieringsnummer: John D. Dingell VA Medical Center)
- 1I01CX001938-01 (U.S. NIH-stipend/kontrakt)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .